Natixis Esperion Therapeutics, Inc. Transaction History

Natixis

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$31.18 - $52.71 $418,560 - $707,579	-13,424 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$30.04 - $51.31 $403,256 - $688,785	13,424 New	13,424 $689,000
Q1 2020 May 14, 2020	SELL	$27.44 - $73.84 $230,688 - $620,772	-8,407 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$35.4 - $59.82 $31,010 - $52,402	876 Added 11.63%	8,407 $503,000
Q3 2019 Nov 13, 2019	SELL	$34.47 - $47.53 $483,683 - $666,940	-14,032 Reduced 65.07%	7,531 $276,000
Q2 2019 Aug 13, 2019	BUY	$40.1 - $52.33 $364,709 - $475,941	9,095 Added 72.95%	21,563 $1 Million
Q1 2019 May 15, 2019	SELL	$40.11 - $53.57 $384,213 - $513,147	-9,579 Reduced 43.45%	12,468 $500,000
Q4 2018 Feb 14, 2019	BUY	$36.99 - $59.11 $534,098 - $853,489	14,439 Added 189.79%	22,047 $1.01 Million
Q3 2018 Nov 14, 2018	SELL	$40.74 - $51.41 $17,762 - $22,414	-436 Reduced 5.42%	7,608 $338,000
Q2 2018 Aug 14, 2018	SELL	$36.2 - $76.4 $30,227 - $63,794	-835 Reduced 9.4%	8,044 $315,000
Q1 2018 May 15, 2018	SELL	$65.94 - $80.76 $78,996 - $96,750	-1,198 Reduced 11.89%	8,879 $642,000
Q4 2017 Feb 14, 2018	BUY	$43.47 - $67.43 $438,047 - $679,492	10,077	10,077 $663,000

207

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $168M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.